Term

AV2

別名: AV2

Overview

最終更新: 2026年7月9日

AV2は、AOMedia（Alliance for Open Media）が開発を進める次世代のオープン動画コーデックである。AV1の後継として、より高い圧縮効率と優れた画質を実現することを目標としている。この技術は、特に低帯域環境下での高品質な映像配信を可能にし、動画ストリーミングサービス、オンライン会議システム、AR/VR（拡張現実/仮想現実）コンテンツ、クラウドゲーミングなど、多岐にわたるデジタルサービスでの活用が期待される。

AV2の開発は、AOMediaが推進するオープンソースプロジェクトの一環として進められている。AV1で培われた技術基盤を継承しつつ、新たな符号化ツールやアルゴリズムを導入することで、圧縮性能のさらなる向上を図る。具体的には、より洗練された動き予測、変換、量子化技術に加え、機械学習を活用した最適化手法の導入も検討されている。これにより、同じビットレートであればAV1よりも高画質を、同じ画質であればより低いビットレートを実現できる見込みだ。

AV2は、既存のH.264やH.265（HEVC）といったプロプライエタリなコーデックに対するオープンな代替として、業界標準化を目指している。Google、Apple、Microsoft、Amazon、Netflixなど、主要なテック企業がAOMediaに参加しており、その普及には強力なエコシステムが期待される。特に、8K以上の超高解像度映像やHDR（ハイダイナミックレンジ）コンテンツの普及が進む中で、AV2はデータ転送コストの削減とユーザー体験の向上に不可欠な技術となるだろう。

Mentioned Articles

4 件

Research Papers

5 件
  • Different leadless pacemakers working in harmony (Aveir in the atrium/Micra AV2 in the ventricle) in a patient with dextrocardia and double outlet right ventricle after high‐risk infected device extraction

    C. English, Dali Fan, Frank F. Ing, D. Cortez

    202410 件引用Semantic Scholar

    Patients with congenital heart disease are at increased risk for requiring cardiac pacing during their lifetime.

  • Comparative Suppressor Activity of AV2, AC2 and AC4 Genes of Tomato Leaf Curl New Delhi Virus Using Image Analysis

    M. Sarkar, Dipinte Gupta, Parimal Sinha, B. Mandal, A. Roy, M. Maruthi

    20255 件引用Semantic Scholar
  • Advancements in Leadless Pacemakers: What the Second-generation Micra AV2 Brings to Cardiac Care.

    C. Garweg, Rik Willems

    20245 件引用Semantic Scholar

    Leadless pacemakers are considered one of the major technological advancements in cardiology in recent years. Many efforts are made to provide physiological atrio-ventricular (AV) pacing. With the first-generation leadless ventricular, dual, dual (VDD) pacemaker, Micra AV (Medtronic, Inc., Minneapolis, MN, USA), a high variability in AV synchrony was reported. A second generation, Micra AV2, is now available for clinical use, promising smarter and higher automatic AV synchrony. This article reviews the different improvements proposed for this new device.

  • Anti-Inflammatory and Antinociceptive Properties of the Quercetin-3-Oleate AV2, a Novel FFAR1 Partial Agonist

    F. Pessina, I. Casini, Alessandra Gamberucci, Gabriele Carullo, C. Signorini, A. Brizzi, Francesca Aiello, A. M. Aloisi, S. Pieretti

    20243 件引用Semantic Scholar

    Free fatty acid receptor 1 (FFAR1) has emerged as the most targeted isoform of the free fatty acid receptors because of its involvement in the modulation of energy balance and its potential role in the control of inflammatory and pain conditions. Quercetin-3-oleate (AV2), recognized as a new FFAR1 partial agonist, was investigated for its ability to modulate inflammation and nociception. Human immortal neuroblastoma SH and the murine macrophagic RAW 264.7 cells were used to evaluate cell viability, the potential cytoprotective activity, and the anti-inflammatory properties of AV2 in vitro. Paw edema, caused by zymosan-A, and the formalin test were used to assess the in vivo anti-inflammatory and antinociceptive effects in CD-1 mice. In vitro, AV2 was devoid of cytotoxicity, significantly reduced ROS in both cell types, and protected RAW 264.7 cells from lipopolysaccharide damage by reducing tumor necrosis factor-α production. Interestingly, AV2 induced a transient elevation of intracellular calcium that was reduced in cells, pre-incubated with the FFAR1 antagonist DC260126. In vivo, AV2 reduced formalin-induced nociception and zymosan A-induced paw edema, and both effects were reversed by the FFAR1 antagonist GW1100. In conclusion, these data strongly support the AV2-mediated antioxidant, anti-inflammatory, and antinociceptive activity. AV2 represents a promising molecule for the clinical management of inflammatory-related pain conditions.

  • Defining AV2‐1 as a novel pharmacological probe to target human and rodent TRPV2

    Andrea Leipe, Julia A. Rocereta, R. Pumroy, Andreas Leffler, Michael Schaefer, Vera Y. Moiseenkova-Bell, K. Hill

    20263 件引用Semantic Scholar

    Transient receptor potential vanilloid 2 (TRPV2) is a non‐selective cation channel implicated in immune cell functions. However, progress in understanding TRPV2 has been limited by a lack of potent and selective pharmacological tools, particularly those targeting the human variant. We aimed to identify and characterise a novel small‐molecule activator of TRPV2.

External Mentions

10 件